Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Taste changes are usually temporary and often improve as the body adjusts to treatment
5-Amino-1MQ Capsules remain important in labs exploring metabolism, cell biology, and aging science
B12 is also a key player in energy metabolism, as it helps the body convert food into glucose, which is then used as fuel by the body
Certain seminal peptides influence sperm motility, adhesion to the oocyte, and polyspermy prevention, suggesting cross-talk between peptide systems in fertility